βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sharbeen George, Kokkinos John, Schulstad Grace, Pandzic Elvis, Youkhana Janet, Ma Zerong, Ignacio Rosa Mistica C, Raina Aparna S, Chiang Shannon, Boyer Cyrille, Haghighi Koroush S, Gunawarman Matthew, Goldstein David, Gebski Val, Pajic Marina, Davis Meagan E, Arkell Oliver S M, Kopecky Chantal, Gonzales-Aloy Estrella, Ishak Alexander, Erkan Mert, Morton Jennifer P, Kavallaris Maria, Gunning Peter W, Hardeman Edna C, Johns Amber, Gill Anthony J, Whan Renee M, Mawson Amanda, Pitiyarachchi Omali, Australian Pancreatic Cancer Genome Initiative, McCarroll Joshua A, Phillips Phoebe A
Аннотация
The microtubule protein βIII-tubulin is a prognostic, pro-survival, and chemoresistance factor in multiple malignancies, including pancreatic ductal adenocarcinoma (PDAC). However, the precise survival mechanisms controlled by βIII-tubulin in cancer remain unknown. Here, we discovered a link between βIII-tubulin and the activation of caspase 8-mediated extrinsic apoptosis. Silencing βIII-tubulin in PDAC cells activated caspase 8, leading to decreased cell viability and growth both in vitro and in vivo. βIII-tubulin knockdown also increased the sensitivity of PDAC cells to extrinsic cell death signals, including TNF-related apoptosis-inducing ligand (TRAIL), TNFα, and FasL. Furthermore, we demonstrated that βIII-tubulin knockdown in PDAC cells, in the absence or presence of TRAIL, increased diffusion and clustering of the TRAIL death receptor DR5 at the cell membrane, inducing extrinsic apoptosis. Nanoparticle delivery of βIII-tubulin siRNA to mouse PDAC tumours reduced tumour growth and increased responsiveness to TRAIL therapy. In patient-derived human PDAC explants, βIII-tubulin silencing reduced tumour cell frequency and improved sensitivity to TRAIL. Finally, we showed that high βIII-tubulin expression in the human PDAC stroma was independently prognostic for poor overall survival. Taken together, silencing βIII-tubulin represents an innovative strategy to activate a suicide signal in PDAC cells and render them more sensitive to microenvironment- and chemotherapy-derived death signals.